Allogene discontinues enrollment in Phase 1 cema-cel CLL trial due to slow accrual

Allogene Therapeutics, Inc.

Discontinued the Phase 1 cohort in ALPHA2 trial for cema-cel in relapsed/refractory CLL after BTKi/BCL2i therapy.
Enrollment slower than anticipated due to emergence of new alternative treatment options.
Interest among investigators remains high but company is reallocating resources to other pipeline programs.
No financial impact or guidance changes disclosed in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.